Plain-English translation of NCT07023731 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new investigational medication called in people with advanced cancers that have a specific genetic change known as KRAS G12D mutation. The medication works by breaking down a mutated protein that helps cancer cells grow, with the goal of slowing or stopping tumor growth. This is the first time this medication will be used in humans.
Many advanced cancers have this specific KRAS G12D mutation, and current treatments don't always work well against it. Researchers believe this new treatment could offer hope for patients whose cancer has stopped responding to standard options.
The trial has two parts. In the first part, small groups of participants receive the medication intravenously (through a vein) at gradually increasing doses, either once a week or every two weeks, to find the safest dose. In the second part, a larger group of people with pancreatic cancer specifically receives the treatment at the dose level determined to be most promising. Throughout the trial, you will have regular visits for blood tests, scans to measure your tumors, and check-ups to monitor for side effects.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States